Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 16 of the 37 sources its claims cite were checked for support.

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Open access

Abstract

A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilance database. Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included. The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4─139] weeks. The median AEC was 2.7 [0.8─90.9] G/L. Eosinophil-related manifestations were reported in 21 of the 37 cases (57%). If administered, corticosteroids were always effective (n = 10 out of 10). Partial or complete remission of eosinophilia was obtained in some patients not treated with corticosteroids, after discontinuation (n = 12) or with continuation (n = 4) of the ICI. The AEC should be monitored in ICI-treated patients. If required by oncologic indications, continuation of ICI may be an option in asymptomatic hypereosinophilic patients, and in corticosteroid responders.

Overview

CoChat Summary

TL;DR

In 37 cases of moderate-to-severe eosinophilia after immune checkpoint inhibitor (ICI) therapy, eosinophil-related manifestations occurred in 21/37 (57%), with median time to absolute eosinophil count (AEC) peak of 15 weeks and median AEC of 2.7 G/L. Corticosteroids were effective in all 10 treated patients, and some patients had remission without corticosteroids after ICI discontinuation or continuation.

Key findings

  • Among 37 included reports, 25 patients received nivolumab, 6 pembrolizumab, 4 ipilimumab, and 2 nivolumab plus ipilimumab; indications were non-small-cell lung cancer (n = 18), melanoma (n = 18), and Hodgkin’s lymphoma (n = 1).
  • Median [range] time to new-onset eosinophilia was 6 [1─52] weeks and to AEC peak was 15 [4─139] weeks; median AEC was 2.7 [0.8─90.9] G/L.
  • Eosinophil-related manifestations were reported in 21/37 cases (57%), affecting skin (n = 10), lung (2 eosinophilic pneumonia, 2 eosinophilic bronchiolitis), kidneys (4 nephritis), liver (2 cholangitis), and heart (1 myocarditis); severity included 1 grade IV, 6 grade III, 8 grade II, and 7 grade I cases, with no deaths attributable to Eo-irAEs.
  • Corticosteroids were always effective when administered (n = 10/10); partial or complete remission also occurred in some patients not treated with corticosteroids after ICI discontinuation (n = 12) or continuation (n = 4).

Methods

  • Observational study of cases recorded at the French national reference center for hypereosinophilic syndromes (CEREO) and the French national pharmacovigilance database (FPVD), searched up to January 15, 2019 and November 1, 2017, respectively.
  • Inclusion required at least one AEC >1 G/L after ICI initiation and/or biopsy-confirmed eosinophil-induced organ damage; patients with other likely eosinophilia etiologies or missing data were excluded.
  • Cases were classified as Eo-ir (no organ dysfunction attributed to eosinophilia) or Eo-irAEs (organ dysfunction considered induced by proven tissue eosinophilia and/or potentially induced by eosinophils); quantitative variables were reported as median [range], and medians compared using Wilcoxon rank sum test.

Limitations

  • The authors state that the retrospective design had inherent limitations: misclassification, missing data, and risk of selection bias due to the FPVD’s self-reporting procedure, which emphasizes the most symptomatic cases.
  • The authors note that data on time from corticosteroid onset to remission were not available for the great majority of cases, and corticosteroid dosage was not specified in the pharmacovigilance reports.
  • The text makes evident that this is a descriptive case series without a control group, so comparative effectiveness or causality cannot be established from these data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1722022

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Flow chart showing the case selection process. AEC: absolute eosinophil count; Eo-irAEs: eosinophil-induced adverse events; Eo-ir: immune-related blood eosinophilia.
Figure 1. Flow chart showing the case selection process. AEC: absolute eosinophil count; Eo-irAEs: eosinophil-induced adverse events; Eo-ir: immune-related blood eosinophilia.CC BY-NC · PubMed Central

Verification

Claims the paper makes

9 Valid · 0 Not valid · 10 Not checked · 37 Own results and interpretations

19 more claims

Create a free account to see all 56 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 38 references

Cited by

See all 59

Metadata

Authors
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., Staumont-Sallé, D., Morschhauser, F., Forestier, A., Groh, M., Launay, D., Hachulla, E., Labalette, M., Kahn, J.-E., & Lefèvre, G.
Affiliations
  • Université de Lille (FR)
  • CHU Dijon Bourgogne (FR)
  • Hôpital Européen Georges Pompidou, Centre Régional de PharmacoVigilance, Assistance Publique-Hôpitaux de Paris
  • Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Inserm (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre Oscar Lambret (FR)
Corresponding author
Lefèvre, Guillaume
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1722022-1722022
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3016188779
Cited by
59
References
38
Citations by year
2026: 4 · 2025: 10 · 2024: 13 · 2023: 7 · 2022: 8 · 2021: 13 · 2020: 2
FWCI
5.65
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
immune checkpoint inhibitors, drug-induced eosinophilia, immune-related adverse events, hypereosinophilic syndrome, absolute eosinophil count, corticosteroid therapy, treatment discontinuation, immune-related pneumonitis, pharmacovigilance
MeSH terms
Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Humans, Databases, Factual, Hypereosinophilic Syndrome, Pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. https://app.cochat.ai/papers/10.1080/2162402x.2020.1722022
The paper
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., Staumont-Sallé, D., Morschhauser, F., Forestier, A., Groh, M., Launay, D., Hachulla, E., Labalette, M., Kahn, J.-E., & Lefèvre, G. (2020). Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1722022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.